Free Radiation Oncology CME | CMEList.com

 


Test your knowledge of interventional oncology Oncology CME
Posted by...Bernard Sklar, MD.
Oncology CME CME Credit hours 3.25 total (for all 7 modules). 
CME Credits Awarded by....The France Foundation in collaboration with the Society of Interventional Oncology.
Cost...........Free.
Instruction Type...Slide-Video Lecture.
Target Audiences...Clinicians practicing interventional oncology (IO) or those who are interested in learning more about IO. 
Educational material updated....October 2017.
Expiration of CME credit...October 2018.
Financial Support...Bayer Healthcare, Biocompatibles, Inc., Boston Scientific, Guerbet LLC, and Medical Device Business Services, Inc. (Ethicon).
Earn CME with these new modules on lung cancer which include education on advances in lung cancer treatment, surgical and radiofrequency-ablative techniques, targeted therapies, and immunotherapies. Each takes less than 30 minutes to complete!  Visit IO University to access this free education now!

Hormone Receptor-Positive Advanced/Metastatic Breast Cancer: A Deeper Look into CDK4/6 Inhibitors Free Oncology CME
Live online June 28, 2017 and available on demand through December 28, 2017.
Posted by...Bernard Sklar, MD.
Free Oncology CME Credit hours..1.0.
CME Credits Awarded by....Albert Einstein College of Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for medical, radiation and surgery oncologists, breast surgeons, oncology nurse practitioners, pharmacists, and other health care professionals who treat patients with breast cancer.
Educational material updated...June 28, 2017.
Expiration of CME credit...December 28, 2017.
Financial Support...Novo Nordisk.
Hormone Receptor-Positive Advanced/Metastatic Breast Cancer: A Deeper Look into CDK4/6 Inhibitors consists of a single lecture, with discussion, by Richard S. Finn, MD. 
After viewing Hormone Receptor-Positive Advanced/Metastatic Breast Cancer, you will be better able to :
• Address the current advances and challenges of treating HR+, HER2- advanced and metastatic breast cancer
• Evaluate new safety and efficacy data of CDK4/6 inhibitors for HR+, HER2- advanced and metastatic breast cancer
• Anticipate and plan effective strategies to manage CDK4/6 inhibitor treatment-related side effects